Poly(ethylene glycol)-modified zirconium phosphate nanoplatelets for improved doxorubicin delivery Academic Article uri icon


  • © 2017 Elsevier B.V. Surface modification of doxorubicin (DOX) intercalated zirconium phosphate (ZrP) nanoparticles (DOX@ZrP) is proposed to improve the potential of this drug delivery system for cancer therapy. The surface of DOX@ZrP nanoparticles was modified with an amorphous layer of Zr(IV) followed by modification with monomethyl-poly(ethylene glycol)-monophosphate (m-PEG-PO3) as a feature to increase the DOX@ZrP biocompatibility. 31P{1H}MAS NMR data shows a new peak at −26 ppm corresponding to the PO43− groups coordinated with Zr(IV) on the surface. Initial MTS cell viability assay reveals that m-PEG-PO3/Zr(IV)/DOX@ZrP exhibits ∼20% higher cytotoxicity than free DOX and the other ZrP materials when human prostate cancer PC3 cells are exposed for 48 h. m-PEG-PO3 polymer coating of DOX@ZrP nanoparticles promise to have a strong impact on the targeting, distribution and degradation of the nanoparticles under physiological environment that should result in a more efficient chemotherapy agent than free doxorubicin.

author list (cited authors)

  • González-Villegas, J., Kan, Y., Bakhmutov, V. I., García-Vargas, A., Martínez, M., Clearfield, A., & Colón, J. L.

citation count

  • 19

publication date

  • November 2017